$NERV News

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

CORRECTION: Minerva Neurosciences Establishes $75M At-The-Market Stock Offering Program With Leerink Partners

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Neurosciences Q1 Adj. EPS $(0.17) Misses $(0.13) Estimate

Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Says First Patient Screened In Confirmatory Phase 3 Clinical Trial Evaluating Roluperidone As Monotherapy For Treatment Of Negative Symptoms Of Schizophrenia

Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences Reveals Data From Its Open-Label Safety Trial Evaluating Roluperidone Co-Administered With Olanzapine At SIRS 2026; Trial Demonstrated No Safety Concerns When Co-Administering Roluperidone And Olanzapine

Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $7